Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

JNJ-64251330

2 clinical trials

2 indications

Indication
Healthy
Indication
Adenomatous Polyposis Coli
Clinical trial
A Phase 1, Open-Label, Multi-Dose Study to Assess the Systemic and Local Tissue Pharmacokinetics and Pharmacodynamics of JNJ-64251330 in Healthy Participants
Status: Completed, Estimated PCD: 2020-12-29
Clinical trial
A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants With Familial Adenomatous Polyposis
Status: Completed, Estimated PCD: 2023-02-15